Natera, Inc. (NASDAQ:NTRA) Receives Average Recommendation of “Buy” from Brokerages

Natera, Inc. (NASDAQ:NTRA) has received an average recommendation of “Buy” from the fifteen brokerages that are currently covering the firm, MarketBeat.com reports. Fifteen analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued a report on the stock in the last year is $120.07.

Several analysts recently issued reports on the stock. Stephens reissued an “overweight” rating and issued a $125.00 price target on shares of Natera in a research report on Friday, August 9th. Canaccord Genuity Group lifted their price objective on shares of Natera from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, August 27th. Robert W. Baird raised their price target on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Piper Sandler reissued an “overweight” rating and set a $150.00 price objective on shares of Natera in a report on Friday, September 13th. Finally, TD Cowen lifted their target price on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, August 9th.

Natera Trading Down 0.4 %

NTRA opened at $123.08 on Friday. The company has a fifty day moving average price of $114.84 and a two-hundred day moving average price of $106.00. Natera has a 1-year low of $36.90 and a 1-year high of $132.01. The company has a market cap of $15.11 billion, a P/E ratio of -39.45 and a beta of 1.53. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. During the same period in the prior year, the business earned ($0.97) EPS. The firm’s revenue for the quarter was up 58.1% on a year-over-year basis. Analysts predict that Natera will post -1.96 EPS for the current fiscal year.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 5,024 shares of the stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52. Following the completion of the sale, the chief executive officer now directly owns 195,686 shares in the company, valued at approximately $25,141,737.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Natera news, insider Jonathan Sheena sold 2,700 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $108.87, for a total transaction of $293,949.00. Following the transaction, the insider now directly owns 301,808 shares of the company’s stock, valued at approximately $32,857,836.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Steven Leonard Chapman sold 5,024 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52. Following the transaction, the chief executive officer now owns 195,686 shares in the company, valued at approximately $25,141,737.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 93,921 shares of company stock valued at $10,551,281. Insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Itau Unibanco Holding S.A. bought a new stake in shares of Natera in the 2nd quarter worth approximately $28,000. Principal Securities Inc. purchased a new position in Natera during the fourth quarter valued at $32,000. Quarry LP boosted its holdings in Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after acquiring an additional 190 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after acquiring an additional 108 shares during the last quarter. Finally, YHB Investment Advisors Inc. bought a new position in shares of Natera during the first quarter valued at $36,000. 99.90% of the stock is currently owned by institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.